 |
2 Companies | 2 Products |
|
|
2 Products | |
0 Diseases | |
2 Trials |  |
18 News |  |
| 123456789101112» |
- | Journal, CAR T-Cell Therapy: Base-edited CAR T cells for combinational therapy against T cell malignancies. (Pubmed Central) - Jan 29, 2022
While APOBEC editors can reportedly exhibit guide-independent deamination of both DNA and RNA, we found no problematic 'off-target' activity or promiscuous base conversion affecting CAR antigen-specific binding regions, which may otherwise redirect T cell specificity. Combinational infusion of fratricide-resistant anti-T CAR T cells may enable enhanced molecular remission ahead of allo-HSCT for T cell malignancies.
- || Clinical, European regulatory, Review, Journal, CAR T-Cell Therapy: Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. (Pubmed Central) - Jan 29, 2022
The model for drug development for cell therapy in paediatric oncology could also involve a 'later stage handoff' to industry after early development in academic hands. Finally, and very importantly, strategies must evolve to ensure appropriate ease of access for children who need and could potentially benefit from these therapies.
- ||| AML BCR-ABL1 de novo often has aberrant lymphoid markers - particularly CD19, CD7, TDT (Twitter) - Jan 26, 2022
- ||| CD34/HLA-DR negative: mNPM1, APL. CD7 positive AML: mCEBPA. CD9/CD25: mFLT3. CD123/CD4/CD56 (1->6) without monocytic markers BPDCN (Twitter) - Jan 26, 2022
- ||| AML with bi-allelic mutation of CEBPA is usually CD7+ :) (Twitter) - Jan 25, 2022
- |||| Clinical: NPM1-mutated AML is usually CD34-negative/CD7-negative and HLA-DR variable. However, a subset of cases NPM1-mutated AML have CD34+/CD7+/HLA-DR+ - these pts have a worse outcome (Twitter) - Jan 25, 2022
- ||| Both CEBPA mutant AML and AML with Inv(3) often have aberrant CD7 expression. The latter often presents with preserved or elevated platelets but unfortunately has a rather dismal prognosis (Twitter) - Jan 25, 2022
- |||| Mycosis Fungoides Pearls CD3+CD4+CD7−CD26− CD8+ = hypopigmented MF Patch = Flat Plaque = Raised scale Tumor = >1cm = T3 = Advanced stage (IIb) Rare subtypes: Pagetoid reticulosis = unilesional on leg, indolent Granulomatous slack skin = slow development of sagging skin (Twitter) - Jan 23, 2022
- | Journal, IO biomarker: Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms. (Pubmed Central) - Jan 13, 2022
Finally, and very importantly, strategies must evolve to ensure appropriate ease of access for children who need and could potentially benefit from these therapies. Single TRBC1 antibody detection of T-cell clonality by flow cytometry is a simple, rapid, and robust assay that could be routinely utilized in flow cytometric laboratories.
- | Journal: Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes. (Pubmed Central) - Jan 13, 2022
Single TRBC1 antibody detection of T-cell clonality by flow cytometry is a simple, rapid, and robust assay that could be routinely utilized in flow cytometric laboratories. The results support iFC as a useful diagnostic tool in MDS.
- || methotrexate IV / Generic mfg., ibuprofen / Generic mfg.
Clinical, Journal, CAR T-Cell Therapy, IO biomarker: Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. (Pubmed Central) - Jan 5, 2022
Oral administration of itraconazole and sulfamethoxazole was performed from day 0 after CAR-T cell infusion...Although grade 1 cytokine-release syndrome (CRS) was diagnosed, it was successfully treated with ibuprofen...After complete remission, the patient received hematopoietic stem cell transplantation (HSCT) and has recovered well to thisdate. Overall, this report suggested that 4SCAR7 could be a safe and effective strategy for the treatment of pediatric patients with high-risk T-cell malignancies.
- || Clinical, Journal: CD2 and CD7 are Sensitive Flow Cytometry Screening Markers for T-lineage Acute Leukemia(s): a study of 465 Acute Leukemia Cases. (Pubmed Central) - Dec 30, 2021
Blasts that lack both uniform CD2 and CD7 expression do not require additional cCD3 testing. We propose that CD2 and CD7 could be utilized in a limited antibody flow cytometry panel as a sensitive, robust, and cost-effective way to screen for a T-lineage acute leukemia.
- | Journal: The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. (Pubmed Central) - Dec 27, 2021
In conclusion, we show that the leukemic phase of ALK-negative ALCL is associated with high-risk biologic features and, in particular, a complex karyotype and TP53 deletion. Compared with the non-leukemic ALK-negative ALCL patients, the patients with a leukemic phase of disease have poorer survival and may require more aggressive treatment.
- | Journal: Immunotherapy for T-Cell ALL and T-Cell NHL. (Pubmed Central) - Dec 25, 2021
Compared with the non-leukemic ALK-negative ALCL patients, the patients with a leukemic phase of disease have poorer survival and may require more aggressive treatment. No abstract available
- | Journal: Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics. (Pubmed Central) - Dec 16, 2021
(c) Gating strategies to identify abnormal T-cells should be based on the identification of subsets with distinctly homogenous immunophenotypic properties that are different from those expected for normal T-cells. (d) The blood concentration of abnormal cells, based on any immunophenotypic abnormalities indicative of MF or SS, should be calculated by either direct enumeration or a dual-platform method, and reported.
- || Review, Journal: Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. (Pubmed Central) - Dec 16, 2021
(b) This immunophenotype is not specific, but can assist in the distinction from non-neoplastic T cells and other subtypes of mature T-cell neoplasm. (c) However, small subsets of normal and reactive T-cells can have an overlapping immunophenotype, and can be distinguished by evaluating for additional changes in antigen expression.
- | Journal: Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. (Pubmed Central) - Dec 16, 2021
(c) However, small subsets of normal and reactive T-cells can have an overlapping immunophenotype, and can be distinguished by evaluating for additional changes in antigen expression. The MF/SS cell quantification method using immunophenotypic aberrancies, as recommended by the ICCS, allows to distinguish MF/SS cells from background benign T-cells and enables for more accurate staging, especially among patients currently being considered to have B0 and B1 stage diseases.
- | Journal: International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors. (Pubmed Central) - Dec 16, 2021
(c) Assay performance must be validated and documented through a validation plan and report, which covers both qualitative and semi/quasi-quantitative assay components (example template provided). (d) Ongoing assay-specific quality monitoring should be performed to ensure consistency.
- | Journal: Physical tuning of galectin-3 signaling. (Pubmed Central) - Dec 16, 2021
Diminished caspase activation downstream of Hexamer signaling led to decreased pannexin-1 hemichannel opening and interleukin-2 secretion, events facilitated by the increased caspase activation downstream of wild-type Gal3 signaling. Thus, synthetic fixation of Gal3 multivalency can impart physical control of its outside-in signaling activity by governing membrane glycoprotein engagement and, in turn, intracellular pathway activation.
- || anti-CD7 CAR-T cell therapy / Shanghai Yake Biotech
P1 data, Journal, CAR T-Cell Therapy: Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. (Pubmed Central) - Dec 16, 2021
P2
Among 20 patients with r/r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile. A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659).
- | Observational data, Retrospective data, Journal: Bone marrow trephine immunohistochemistry is useful in characterizing malignancy-associated myelonecrosis: A retrospective observational study. (Pubmed Central) - Dec 16, 2021
A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659). Myelonecrosis may retain tumor antigenicity, and immunohistochemistry using selected panel of antibodies should be tried in such challenging cases for an early presumptive diagnosis and further decision making.
- | Biomarker, Journal: Evaluation of the International Society for Cutaneous Lymphoma Algorithm for the Diagnosis of Early Mycosis Fungoides. (Pubmed Central) - Dec 16, 2021
Furthermore, TCR-γ and β chain rearrangements were more frequently detected in early MF than in non-MF cases. Based on these findings, we propose CD5 and CD7 deficiency as mandatory immunopathologic criteria and PCR-based testing for TCR-γ and β chains as required molecular/biologic criteria to improve the efficiency of early MF diagnosis using the ISCL algorithm.
- ||||| Clinical, CAR T-Cell Therapy: #ASH21 High Effectiveness and Safety of Anti-CD7 #CARTCells in Treating R/R T-ALL - Peihua Lu, MD Hebei Yanda Lu Daopei Hospital (Twitter) - Dec 12, 2021
- |||||| Minimal residual disease: Yang- Cd7 car-t for T-ALL. 4-1bb. Crispr gene editing to prevent fraticide (abs 1696). N=14. 100% manufacture rate. Med 5 line of tx. 93% CR/MRD-ve. 11/13 went to allo. 1 gr3 CRS. No severe ICANS. Med persist 52.5 days. Med Peak by day 15. #ASH21 #leusm #tcell (Twitter) - Dec 12, 2021
- ||||| Preclinical: #ASH21 #leusm #celltx Lu: CD7 CART in T-ALL. CD28/41BB costim. Assessed impact of selecting or engineering (KO7CAR) CD7neg CART to prevent fratricide vs non-selected (NS7CAR). When NS7CAR used, fratricide selected CD7neg CAR in vivo and NS=K in vitro and xenograft activity (Twitter) - Dec 12, 2021
- | anti-CD7 CAR-T cells / PersonGen Biomedicine
Journal, CAR T-Cell Therapy: Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies. (Pubmed Central) - Dec 10, 2021
Furthermore, we confirmed that the antitumor activity of CD7-CAR-T cells was positively correlated with the antigen density of tumor cells. This strategy adapts well with current clinical-grade CAR-T-cell manufacturing processes and can be rapidly applied for the therapy of patients with CD7 malignancies.
- || CARS beyond CD5 , CD7 and CD30 #ASH21 (Twitter) - Dec 10, 2021
- Senl_NS7CAR / Avalon GloboCare
First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL) (GWCC - Hall B5, Level 1) - Dec 4, 2021 - Abstract #ASH2021ASH_6968;
P=N/A
Prior to the CAR-T cells infusion, patients received systemic bridging chemotherapy due to rapid disease progression and then all patients received intravenous fludarabine (30mg/m 2 /d) and cyclophosphamide (300mg/m 2 /d) (FC) lymphodepleting chemotherapy for 3 consecutive days (Day -5 to Day -3)...Conclusion This study demonstrated that CD7-targeted CAR-T therapy offers an opportunity to achieve CR for CD7-positive MPAL patients even for those who relapsed post-transplant. Safety was manageable, however, more data on additional patients and longer observation times are needed to further evaluate the efficacy of CD7 CAR-T products.
- || (2/7) 🩸Increased CD8/CD4 T-cell ratio 🩸Loss of CD7 in these CD8+ predominant T-cells #hemepath #pathtwitter @aravindranmd @DrMNichols @mohdbarouqa @feldstej @KirillLyapichev (Twitter) - Dec 2, 2021
- || Clinical, Journal, IO biomarker: Association of lymphocyte subsets with mortality in severe COVID-19 pneumonia patients. (Pubmed Central) - Dec 2, 2021
Altogether, CD7 loss on T lymphocytes and CD4+ T cell count below 200/ml revealed a significant relationship with mortality. Considering T lymphocytes and T cell subgroup count could have a predictive value for patients suffering from COVID-19.
- | Journal, IO biomarker: Melanocytes in black-boned chicken have immune contribution under infectious bursal disease virus infection. (Pubmed Central) - Dec 1, 2021
These changes in gene expression were highly associated with microtubule-based movement, antigen processing and presentation, defense against viruses, and innate immune responses. Our results indicated that the widely distributed melanocytes in Silky Fowl could migrate to play important innate immune roles during virus infection.
- | Journal: Occurrence and molecular characterization of Cryptosporidium spp., Giardia duodenalis, Enterocytozoon bieneusi, and Blastocystis sp. in captive wild animals in zoos in Henan, China. (Pubmed Central) - Nov 29, 2021
Our study has expanded the host ranges of these four pathogens. The data indicate that animals in zoos can commonly be infected with these four zoonotic pathogens, and animals in zoos are potential sources of zoonotic infections in humans.
- THE ROLE OF SUBPOPULATIONS OF MOBILIZED PERIPHERAL HEMATOPOIETIC STEM CELLS IN THE RESTORATION OF HEMATOPOIESIS DURING HIGH-DOSE CHEMOTHERAPY IN CANCER PATIENTS (Eliezer Rachmilewitz) - Nov 27, 2021 - Abstract #EHOC2021EHOC_374;
Mobilization effect of SC individual subsets is related with disease type. To achieve fast recovery of granulocyte lineages after HSC autologous or allogeneic transplantation one should not focus only on proportion of committed myeloid HSC: optimal HSC content to be transplanted should be in a certain balance.
- WU CART 007 / Wugen
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) () - Nov 24, 2021 - Abstract #ASH2021ASH_6566;
Response will be assessed on Cycle 1 Day 28 (± 1 days), and at Months 3, 6, 12, and 24, by bone marrow aspirate and biopsy and PET/CT if indicated. Response will be defined as per modified NCCN Guidelines Version 2.2020.
- Chronic Lymphocytic Leukemia, T-Cell Large Granular Lymphocytic Leukemia in a Pediatric Patient without Underlying Condition () - Nov 24, 2021 - Abstract #ASH2021ASH_6500;
Extrapolated from limited literature, two management options are considered: watch and wait approach versus early initiation of immunosuppressant chemotherapy. Improved diagnostics can aide management strategies in this patient population.
- anti-CD7 CAR-T cells / PersonGen Biomedicine, Actemra IV (tocilizumab) / Roche, JW Pharma
Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation () - Nov 24, 2021 - Abstract #ASH2021ASH_6479;
No organ dysfuction and immune effector cell-associated neurotoxicity syndrome were observed. In general, we showed for the first time that the nanobody derived CD7-CART with PEBL technology was a potent and safe salvage therapy in a relapsed/refractory ETP-ALL/LBL patient with high tumor burden.
- | Journal: Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC. (Pubmed Central) - Nov 17, 2021
The current study presents an evaluation system based on immunophenotyping, which provides a more accurate prognostic evaluation tool for TNBC patients. Differentially expressed genes can be targeted to improve treatment of TNBC.
- | Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy. (Pubmed Central) - Nov 12, 2021
LINC00426, with significant correlation with immune cell fraction, shows potential prognostic value in ccRCC patients. Our findings provide a strategy in exploring biomarkers with prognostic significance and significant association with the fraction of immune cells.
- || Clinical, Journal: Hypopigmented Mycosis Fungoides: A Clinical and Histopathology Analysis in 9 Children. (Pubmed Central) - Nov 11, 2021
HMF could gradually seem as scaly erythema based on hypopigmented patches. The histopathology indicated a more advanced stage of the scaly erythema lesions than hypopigmented patches.
- || Clinical, Journal, CAR T-Cell Therapy: Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. (Pubmed Central) - Nov 11, 2021
The histopathology indicated a more advanced stage of the scaly erythema lesions than hypopigmented patches. No abstract available
- || Clinical, Retrospective data, Journal, IO biomarker: Clinicopathological features and prognosis of the skeletal-muscle cytotoxic T-cell lymphoma (Pubmed Central) - Nov 8, 2021
Tumor cells show morphologic characteristics of muscle invasion and myositis-like feature. It also shows CD8>CD4immunophenotype, cytotoxic molecular pattern and is associated with low clinical stage and good prognosis.
- cyclosporine / Generic mfg.
Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma after Donor-Derived CD7- Chimeric Antigen Receptor T-Cell Therapy (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5623;
Donor-derived CD7-CART combined with allo-HSCT has shown powerful anti-T-ALL/T-LBL effects and good safety profile. The existence of CD7-CART early after transplant had no influence on engraftment and may contribute to prolonged anti-tumor effect.
- The Impact of the Immunophenotyping Characteristics of Patients’ Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5528;
P1
Conclusion The results indicate that the success rate of CD7 - CAR-T manufacturing is positively correlated with higher viability, lower CD3 + and higher CD4 + of PBMC. There was no significant difference among P4 (CR more than 15 months), P7 (CD7 - relapse at 6 th month after CR) and P8 (CD7 - relapse at 3rd month after CR).
- CD7-CAR-T / PersonGen Biomedicine
A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5527;
P1
There was no significant difference among P4 (CR more than 15 months), P7 (CD7 - relapse at 6 th month after CR) and P8 (CD7 - relapse at 3rd month after CR). Autologous CD7 CAR-T represents a promising immunotherapy for r/r T-ALL/LBL and exhibited encouraging clinical efficacy and safety in treating r/r T-ALL/LBL and ETP-ALL/LBL.
- Decoding Clonal Evolution in Relapsed T Cell Acute Lymphoblastic Leukemia at Single Cell Resolution (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5166;
By tracking transcriptomic profiles within and across Dx_Rel T-ALL pairs, we further identified distinct clonal evolutionary patterns, which may determine diversified fates of leukemic clones in response to therapeutic pressures. In the meantime, we provided a comprehensive phenotypic view on "normal" T cells under leukemic prevalence and re-occurrence, extending significant implications for future precise immunotherapies.
- Cite-Seq Reveals Distinct Patterns and Potential Mechanisms of Relapse in Pediatric AML (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5141;
An exception is CD7, which was enriched at relapse in 50% of our cases and represents a potential therapeutic target. Analysis of more cases will refine these relapse patterns, reveal potential mechanisms of chemoresistance and inform the development of novel therapies.
- Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4465;
P=N/A, P1
However, the incidence of CRS and ICANS did not increase following CD7 CAR-T infusion. More patients and long-term observation are needed to confirm these results and to improve clinical management of patients treated with CAR-T cellular therapies.
- Ex Vivo Production of Large Numbers of Genetically Modified NK Cells from Cord Blood or Mobilized Peripheral Blood CD34+ Cells Using Notch Ligand Delta-like 4 Culture System (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4422;
These data suggests that our DLL4 culture system, along with feeder-free NK cell differentiation is a unique combination that is able to give rise to high number of pure NK cell population with high cytotoxic potential. These results lay a foundation towards an easier approach to NK cell therapy for effective treatment of cancers and viral infections, which will be developed in collaboration with Smart Immune Inc.
- WU CART 007 / Wugen
Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4416;
Conclusions These preclinical studies support the use of WU-CART-007 in clinical trials and highlight the potential of WU-CART-007 to be a well-tolerated and active therapy for patients with CD7+ T-cell malignancies. A first in human Phase 1/2 trial in patients with R/R T-ALL/LBL is currently open for enrollment (NCT# 04984356).
- RVU120 / Ryvu Therap
Inhibition of Cyclin Dependent Kinase 8(CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukaemia (T-ALL) (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3869;
P1
Further clinical study is warranted to study the efficacy of RVU120 and CDK8 inhibition in T-ALL. Keywords: CDK8, RVU120, apoptosis, T-ALL, LICs in PDX model Reference 1 Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. Blood 129 , 1113-1123, doi:10.1182/blood-2016-10-706465 (2017).